Inclusive list of disease modifying medications FDA approved for multiple sclerosis.
Teva Pharmaceuticals announced that the phase 2/3 ARTISTS 1 and phase 3 ARTISTS 2 trials of deutetrabenazine in pediatric patients with moderate to severe Tourette Syndrome did not meet the primary end point.
The FDA has granted Orphan Drug designation to RT001 (Retrotope) for the treatment of progressive supranuclear palsy (PSP).
The FDA has expanded the approval of vigabatrin to include treatment of refractory complex partial seizures in patients aged 2 to <10 years of age.
The Food and Drug Administration has granted Orphan Drug designation to zilucoplan for the treatment of generalized myasthenia gravis and other rare, tissue-based complement-mediated diseases.